![]() Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin (TropicALL) is a multicenter, randomized controlled open-label trial conducted in the Netherlands. Here, we present the protocol of a randomized controlled trial in which the efficacy and safety of thromboprophylaxis with high prophylactic dose LMWH versus no thromboprophylaxis will be assessed in children treated for primary ALL with asparaginase. However, the efficacy of thromboprophylaxis with LMWH during ALL treatment has never been investigated in a randomized design. Prospective cohort studies in which prophylactic low-molecular-weight heparin (LMWH) was used to prevent VTE showed lower VTE risk than in historic control cohorts, with a negligible bleeding risk. An important cause is the intensive use of asparaginase. Venous thromboembolism (VTE) is a common and severe complication during treatment of acute lymphoblastic leukemia (ALL).
0 Comments
Leave a Reply. |